BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, April 12, 2026
Home » Topics » Regulatory » Patents

Patents
Patents RSS Feed RSS

Cancer

Hainan Sparkle Therapeutics discovers new USP1 inhibitors

Nov. 2, 2022
Hainan Sparkle Therapeutics Co. Ltd. has described ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.
Read More
Neurology/Psychiatric

Shandong Luye Pharmaceutical presents new compounds for Parkinson’s disease

Nov. 2, 2022
Shandong Luye Pharmaceutical Co. Ltd. has divulged cannabidiol prodrugs reported to be useful for the treatment of cancer, tremor, epilepsy, anxiety disorder, inflammatory disorders, pain, multiple sclerosis and Parkinson's disease, among others.
Read More
Cancer

Lifearc describes new ULK inhibitors

Nov. 2, 2022
Lifearc has identified pyrimidine compounds acting as serine/threonine-protein kinase ULK inhibitors reported to be useful for the treatment of chronic myeloid leukemia.
Read More
Cancer

University of Basel divulges new PI3K inhibitors

Nov. 2, 2022
The University of Basel has synthesized triazine derivatives acting as phosphatidylinositol 3-kinase (PI3K) inhibitors reported to be useful for the treatment of cancer, neurological and immunological disorders.
Read More
Cancer

Rhizen Pharmaceuticals and Incozen Therapeutics patent new PARP inhibitors

Nov. 2, 2022
Rhizen Pharmaceuticals SA and Incozen Therapeutics Pvt. Ltd. have disclosed salts of NAD+ ADP-ribosyltransferase poly [ADP-ribose] polymerase (PARP) inhibitors reported to be useful for the treatment of cancer, bone, cardiovascular, immunological, inflammatory and respiratory disorders, metabolic diseases and thrombosis.
Read More
Neurology/Psychiatric

Cosmas Therapeutics Development synthesizes new melatonin MT2 receptor agonists

Oct. 31, 2022
Cosmas Therapeutics Development Inc. has discovered prodrugs of UCM-924 acting as melatonin MT2 receptor agonists reported to be useful for the treatment of pain, depression, diabetes, sleep and anxiety disorders.
Read More
Neurology/Psychiatric

Leitat Technological Center identifies new SIGMAR1 and/or TMEM97 ligands

Oct. 31, 2022
Leitat Technological Center has patented sigma non-opioid intracellular receptor 1 (SIGMAR1) and/or sigma intracellular receptor 2 (TMEM97) ligands reported to be useful for the treatment of pain and neurological disorders.
Read More
Cancer

Hangzhou Innogate Pharma presents new GTPase KRAS mutant inhibitors

Oct. 31, 2022
Hangzhou Innogate Pharma Co. Ltd. has synthesized GTPase KRAS (Gly12Asp mutant) inhibitors reported to be useful for the treatment of cancer.
Read More
Cancer

Medipure Holdings divulges new cannabidiol compounds

Oct. 31, 2022
Medipure Holdings Inc. has described cannabidiol (CBD) prodrugs reported to be useful for the treatment of pain, epilepsy, cancer, inflammation, psychosis and neurological, eye and immunological disorders.
Read More
Cancer

Jacobio Pharmaceuticals discloses new TP53 mutant stabilizers

Oct. 31, 2022
Jacobio Pharmaceuticals Co. Ltd. has patented cellular tumor antigen p53 (TP53) (Tyr220Cys mutant) stabilizers reported to be useful for the treatment of cancer.
Read More
Previous 1 2 … 448 449 450 451 452 453 454 455 456 … 3800 3801 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 10, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 7, 2026
  • MMP inhibitors divulged in Accure Therapeutics patent

    BioWorld Science
    Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
  • MSD discloses new HCN1/2 blockers

    BioWorld Science
    Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
  • Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent

    BioWorld Science
    Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing